DOCTORS (este contenido es más científico)
Despite an annual spending of $ 7.8 billion on screening mammograms in the United States, more than 40,000 women die from breast cancer each year. Invasive breast cancer is the leading cause of death in this country for women between the ages of 35-54. According to the National Cancer Institute, in 2010, the cost of breast cancer treatment was approximately $ 16.5 billion in the United States, higher than any other type of cancer. This is expected to exceed $ 20.5 billion by 2020. Individual costs vary, depending on the stage of malignancy and the treatment options selected. Obviously, our current approach to the problem is inadequate.
Process and equipment:
Accuracy / Automation:
The SonoCiné robot automates the scan acquisition process by compensating for the sonographer’s probe manipulation and reducing human error. The robot helps maintain scan row overlap and provides automated nipple placement, with an intuitive, tactile workflow built into RIS and PACS.
SonoCiné captures a slice every 400µ and therefore provides enough images to identify masses as small as 3-5mm in diameter. Smooth video playback and visual navigation allow clinicians a more complete view of a potential finding.
SonoCiné AWBUS is FDA approved, quality controlled and connects to any high quality ultrasound machine. The sonographer ensures transducer contact while the robot scans the entire breast in linear rows.
A prospective, blinded clinical trial showed that adding a blind AWBUS exam to a mammogram found more and smaller cancers than with mammography alone.
Source: European Radiology, March 10, 2010.
Kevin Kelly Multi-Center Test
- 6,425 exams
- 46 total cancers found
- 39 invasive and 7 DCIS
- 23 cancers visualized by mammography
- 15 cancers visualized by both SonoCiné and mammography
- 23 cancers visualized only by SonoCiné
If you would like to request a document other than one of the documents listed below, please contact us.
OJO!!! Estos son links de estudios publicados!!!!!!!!